Access
To read this story in full you will need to login or make a payment (see right).
Letters to Nature
Nature 414, 751-756 (13 December 2001) | doi:10.1038/414751a; Received 27 June 2001; Accepted 26 October 2001
Open Innovation Challenges
-
Novel Approaches to Protecting Maize from Insect Damage
The Seeker is looking for novel approaches to protecting maize from insect damage. This Challenge re...
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
nature jobs
Pharmacology Group Leader
- S*BIO Pte Ltd
- Singapore
Head of Analytical R&D
- Syngene International Limited
- Bangalore 560 099 India
Imperfect vaccines and the evolution of pathogen virulence
Sylvain Gandon1,2, Margaret J. Mackinnon1,2, Sean Nee1 & Andrew F. Read1
- Institute of Cell, Animal and Population Biology, The University of Edinburgh, Edinburgh EH9 3JT, UK
- These authors contributed equally to this work
Correspondence to: Sylvain Gandon1,2 Correspondence and requests for materials should be addressed to S.G. (e-mail: Email: Sylvain.Gandon@ed.ac.uk).
Abstract
Vaccines rarely provide full protection from disease. Nevertheless, partially effective (imperfect) vaccines may be used to protect both individuals and whole populations1, 2, 3. We studied the potential impact of different types of imperfect vaccines on the evolution of pathogen virulence (induced host mortality) and the consequences for public health. Here we show that vaccines designed to reduce pathogen growth rate and/or toxicity diminish selection against virulent pathogens. The subsequent evolution leads to higher levels of intrinsic virulence and hence to more severe disease in unvaccinated individuals. This evolution can erode any population-wide benefits such that overall mortality rates are unaffected, or even increase, with the level of vaccination coverage. In contrast, infection-blocking vaccines induce no such effects, and can even select for lower virulence. These findings have policy implications for the development and use of vaccines that are not expected to provide full immunity, such as candidate vaccines for malaria4.
To read this story in full you will need to login or make a payment (see right).

